Cells from tumour #2 were less sensitive to anti-IGF1R treatment in all assay formats, but responded to combination treatment with anti-IGF1R and anti-EGFR antibodies (Additional file 1: Figure S1C/D). The gene discussed is EGFR; the disease is neoplasm.